Filter Results:
(5,923)
Show Results For
- All HBS Web
(5,923)
- People (7)
- News (948)
- Research (3,830)
- Events (68)
- Multimedia (68)
- Faculty Publications (2,775)
Show Results For
- All HBS Web
(5,923)
- People (7)
- News (948)
- Research (3,830)
- Events (68)
- Multimedia (68)
- Faculty Publications (2,775)
- May 1990 (Revised July 1991)
- Case
Workbench Pricing Strategy
An abridged version of Workbench, most notably the results of two customer surveys, given in their complete form in Workbench. Focuses on the pricing decision for a small contemporary furniture retailer. Should Workbench continue its highly promotional pricing policy... View Details
Ortmeyer, Gwendolyn K. "Workbench Pricing Strategy." Harvard Business School Case 590-115, May 1990. (Revised July 1991.)
- 11 Oct 2021
- News
Nobel Winners Found Economic Experiments in the Real World
- 25 Oct 2019
- HBS Seminar
SBBI Seminar: Some Executive Views of Technology on the Future of Work
Dante Roscini
Dante Roscini holds the Professor of Management Practice Chair endowed by the MBA Class of 1952 at Harvard Business School. He joined the faculty in 2008 after a two-decades-long career in finance. He currently teaches the course Business, Government, and the... View Details
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.
- 20 Nov 2012
- Working Paper Summaries
Pay Harmony: Peer Comparison and Executive Compensation
Keywords: by Claudine Gartenberg & Julie Wulf
- 1 Apr 2013
- Interview
Restoring U.S. Competitiveness: Professor Michael Porter in an interview with Charlie Rose
"There is an historic opportunity right now for business and government to work together [to restore U.S. competitiveness]." Professor Porter discusses the eight federal policy priorities that business leaders and policymakers, liberals and conservatives agree will... View Details
Keywords: U.S. Competitiveness; Competition; Policy; Global Strategy; Business and Government Relations; United States
Porter, Michael E. "Restoring U.S. Competitiveness: Professor Michael Porter in an interview with Charlie Rose." Charlie Rose (Television program), April 1, 2013.
- 19 Aug 2021
- Op-Ed
Don't Ignore Your Employees' Misery—TAKE Control
As organizations eagerly reopen their doors more than a year after the COVID-19 pandemic began, many will be surprised to watch their employees walk out—for good. Companies have been quick to set blanket policies that range from a full return to offices to fully remote... View Details
Keywords: by Hise O. Gibson and MaShon Wilson
- 27 Mar 2015
- Working Paper Summaries
Capital Requirements, Risk Choice, and Liquidity Provision in a Business Cycle Model
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details
Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "The Impact of the Entry of Biosimilars: Evidence from Europe." Review of Industrial Organization 53, no. 1 (August 2018): 173–210.
- 01 Jul 2025
- Video
Opportunities in the clean energy transition
- Video
Louisa Mojela & Gloria Serobe
Louisa Mojela and Gloria Serobe, Co-Founders and leading executives of WIPHOLD, discuss what South Africa's Black Economic Empowerment (BEE) policies and legislation have meant for the company and the country's business landscape as a whole. View Details
Louis E. Caldera
Louis Caldera is a Senior Lecturer of Business Administration at Harvard Business School. He teaches Leadership and Corporate Accountability, a required first-year course in the MBA program. He has previously taught law school courses on corporate... View Details
- 27 May 2019
- News
Not So Fast: Cashless Backlash Delays Move to Walletless Economy
- Video
Melek El Nimer
Melek El Nimer, founder of the Social Support Society and Unite Lebanon Youth Project in Lebanon, details the policies her organizations have put in place to shield them from corruption, which she describes as a pervasive problem in Lebanon. View Details
- May 2009
- Article
The Empirical Impact of Intellectual Property Rights on Innovation: Puzzles and Clues
By: Josh Lerner
Economists have long seen the patent system as a crucial lever through which policymakers affect the speed and nature of innovation in the economy. It is not surprising, then, that the profound changes which have roiled the global patent system over the past 20 years... View Details
Keywords: Economy; Policy; Innovation and Invention; Intellectual Property; Rights; Business and Government Relations
Lerner, Josh. "The Empirical Impact of Intellectual Property Rights on Innovation: Puzzles and Clues." American Economic Review: Papers and Proceedings 99, no. 2 (May 2009): 343–348. (Earlier version distributed as National Bureau of Economic Research Working Paper No. 8977.)
- 25 Jan 2012
- Research & Ideas
A Few Firms Have Outsized Influence in D.C.
in the twisted web of Washington fundraising and lobbying that can definitively prove dollar x bought result y. Perhaps that's why there has been such little empirical research among economists on the issue. "The whole perspective of how firms influence View Details
Keywords: by Michael Blanding
- 14 Sep 2017
- News
Study: US Government Its Own Worst Enemy
- 14 Oct 2016
- Working Paper Summaries
A Welfarist Role for Nonwelfarist Rules: An Example with Envy
Keywords: by Matthew Weinzierl